ATR and small cell lung carcinoma: A randomized phase II trial (NCT04768296) is assessing the efficacy of the ATR inhibitor Berzosertib in conjunction with topotecan for the treatment of relapsed, platinum-resistant SCLC, with the release of data anticipated.